Butyrylcholinesterase K variant and the APOE-ε4 allele work in synergy to increase the risk of coronary artery disease especially in diabetic patients

Molecular Biology Reports

Volumn 37, Issue 4, 2010, Pages 2083-2091

  Vaisi Raygani, Asad ^a   Rahimi, Zohreh ^b   Tavilani, Haidar ^c   Pourmotabbed, Tayebeh ^d  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Apolipoprotein E; Butyrylcholinesterase K variant; Coronary artery disease; Genetics; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN E4; CHOLESTEROL; CHOLINESTERASE; CHOLINESTERASE K; GENOMIC DNA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DNA DETERMINATION; FEMALE; GENOTYPE; HUMAN; IRAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; BLOOD; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; MIDDLE AGED; RISK; SEXUAL DEVELOPMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; APOLIPOPROTEIN E4; BUTYRYLCHOLINESTERASE; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; IRAN; LIPIDS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; SEX CHARACTERISTICS;

EID: 77953165868     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-009-9666-4     Document Type: Article

References (38)

1. Kalix S, Meynet MCB, Garin MCB, James RW (2001) The apolipoprotein e2 allele and the severity of coronary artery disease in Type 2 diabetic patients. Diabet Med 18:445-450
2. Mahfouz RAR, Sabbagh AS, Zahed LF, Mahfoud ZR, Kalmoni RF, Otrock ZK, Taher AT, Zaatari GS (2006) Apolipoprotein E gene polymorphism and allele frequencies in the Lebanese population. Mol Bio Rep 33:145-149
3. Jaikaran ETAS, Clark A (2001) Islet amyloid and Type 2 diabetes: From molecular misfolding to islet pathophysiology. Biochim Biophys Acta 1537:179-203
4. Zimmet PZ (1999) Diabetes epidemiology as a tool to trigger diabetes research and care. Diabetologia 42:499-518
5. Hirashiki A, Yamada Y, Murase Y, Suzuki Y, Kataoka H, Morimoto Y, Tajika T, Murohara T, Yokota M (2004) Association of gene polymorphisms with coronary artery disease in lowor high-risk subjects defined by conventional risk factors. J Am Coll Cardiol 44(1):209-210
6. Nassar BA, Rockwood K, Kirkland SA, Ransom TP, Darvesh S, Macpherson K, Johnstone DE, O'Neill BJ, Bata IR, Andreou P, Jeffery JS, Cox JL, Title LM (2006) Improved prediction of early-onset coronary artery disease using APOE epsilon4, BChEK, PPARgamma2 Pro12 and ENOS T-786C in a polygenic model. Clin Biochem 39(2):109-114
7. Nassar BA, Darvesh S, Bevin LD, Rockwood K, Kirkland SA, O'neill BJ, Bata IR, Johnstone DE, Title LM (2002) Relation between butyrylcholinesterase K variant, paraoxonase 1 (PON1) Q and R and apolipoprotein E epsilon 4 genes in early-onset coronary artery disease. Clin Biochem 35(3):205-209
8. Hashim Y, Shepherd D, Wiltshire S, Holman RR, Levy JC, Clark A, Cull CA (2001) Butyrylcholinesterase K variant on chromosome 3 q is associated with Type II diabetes in white caucasian subjects. Diabetologia 44:2227-2230
9. Kharrazi H, Vaisi Raygani A, Sabokroh AR, Pourmotabbed T (2006) Association between apolipoprotein E polymorphism and coronary artery disease in the Kermanshah population in Iran. Clin Biochem 39:613-616
10. Vaisi Raygani A, Rahimi Z, Nomani H, Tavilani H, Pourmotabbed T (2006) The presence of apolipoprotein a°4 and a°2 alleles augments the risk of coronary artery disease in type 2 diabetic patients. Clin Biochem 40:1150-1156
11. Vaisi Raygani A, Rahimi Z, Entezami H, Kharrazi H, Bahrhemand F, Tavilani H, Rezaei M, Kiani A, Nomanpour B, Tavilani H, Pourmotabbed T (2008) Butyrylcholinesterase K variants increase the risk of coronary artery disease in the population of western Iran. Scandin J Clin and Lab Invest 68(2): 123-129
12. Lepienski LM, Alcantara VM, Souza RL, Rea RR, Chautard- Freire-Maia EA (1993) Variant K of butyrylcholinesterase and types 1 and 2 of diabetes mellitus. Clin Sci Lond 85(1):77-81
13. Raygani AV, Zahrai M, Solt Anzadeh A, Doosti M, Javadi E, Pourmotabbed T (2004) Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in alzheimer's disease. Neurosci Lett 371(2-3):142-146
14. WHO (1999) Study Group Report of a WHO consultation: Part 1: Diagnosis and classification of diabetes mellitus. World Health Organization, Geneva
15. Johan SWM, Weitzner G, Rozen R (1991) A rapid procedure for extracting genomic DNA from leukocytes. Nucleic Acids Res 19:408
16. Jenese FS, Nielsen LR, Schwartz M (1996) Detection of the plasma cholinesterase K variant by PCR using amplification- created restriction site. Hum Heard 46:26-31
17. Wenham PR, Price WH, Blandell G (1991) Apolipoprotein E genotyping by onstage PCR. Lancet 337:1158-1159
18. Humphries SE, Ridker PM, Talmud PJ (2004) Genetic testing for cardiovascular disease susceptibility: A useful clinical management tool or possible misinformation. Arterioscler Thromb Vasc Biol 24:628-636
19. Saito M, Eto M, Nitta H, Kanda Y, Shigeto M, Nakayama K, Tawaramoto K, Kawasaki F, Kamei S, Kohara K, Matsuda M, Matsuki M, Kaku K (2004) Effect of apolipoprotein E4 allele on plasma LDL cholesterol response to diet therapy in type 2 diabetic patients. Diabetes Care 27(6):1276-1280
20. Lehmann DJ, Nagy Z, Litchfield S, Cortina Borja M, Smith DA (2000) Association of butyrylcholinesterase K variant with cholinesterasepositive neuritic plaques in the temporal cortex in late-onset alzheimer's disease. Hum Genet 106:447-452
21. Abbott CA, Mackness MI, Kumar S, Olukoga AO, Gordon C, Arrol S, Bhatnagar D, Boulton AJ, Durrington PN (1993) Relationship between butyrylcholiesterase activity, hypertriglyceridemia and insulin sensitivity in diabetes mellitus. Clin Sci 85:77-81
22. Duman BS, Ozturk M, Yilmazer S, Hatemi H (2004) Apolipoprotein E polymorphism in Turkish subjects with Type 2 diabetes mellitus: Allele frequency and relation to serum lipid concentrations. Diabetes Nutr Metab 7(5):267-274
23. Isbir T, Yilmaz H, Agachan B, Karaali ZE (2003) Cholesterol ester transfer protein, apolipoprotein E and lipoprotein lipase genotypes in patients with coronary artery disease in the Turkish population. Clin Genet 64(3):228-234
24. Lepienski LM, Souza RL, Chautard-Freire-Maia EA, Alcantara VM, Rea RR (2006) Variant K of butyrylcholinesterase and risk of early-onset type 1 diabetes mellitus in Euro-Brazilians. Diabetes Obes Metab 8(6):709-711
25. Corbo RM, Vilardo T, Ruggeri M, Gemma AT, Scacchi R (1999) Apolipoprotein E genotype and plasma levels in coronary artery disease. a case control study in the Italian population. Clin Biochem 32(3):217-222
26. Guang-da X, Xiang-Jiu Y, Lin-Shuang Z, Zhi-Song C, Yu-Sheng H (2005) Apolipoprotein e4 allele and the risk of CAD death in type 2 diabetes mellitus with ischaemia electrocardiographic change. Diabetes Res Clin Pract 68(3):223-229
27. Johansen A, Nielsen EM, Andersen G, Hamid YH, Jensen DP, Glumer C, Drivsholm T, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O (2004) Large-scale studies of the functional K variant of the butyrylcholinesterase gene in relation to Type 2 diabetes and insulin secretion. Diabetologia 47(8):1437-1441 (Pubitemid 39232430)
28. Wilson PWF, Schaefer EJ, Larson MG, Ordovas JM (1996) Apolipoprotein E alleles and risk of coronary disease: A metaanalysis. Arterioscler Thromb Vasc Biol 16:1250-1255
29. Mero N, Malmstrom R, Steiner G, Taskinen MR, Syvanne M (2000) Postprandial metabolism of apolipoprotein B-48- and B- 100-containing particles in type 2 diabetes mellitus: Relations to angiographically verified severity of coronary artery disease. Atherosclerosis 150:67-177
30. Ou T, Yamakawa-Kobayashi K, Arimani T et al (1998) Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: A case-control study. Atherosclerosis 137:23-28
31. Gensini GF, Comeglio M, Colella A (1998) Classical risk factors and emerging elements in the risk profile for coronary artery disease. Eur Heart J 19(A):53-61
32. Singh PP, Naz I, Gilmour A, Singh M, Mastana S (2006) Association of APOE (Hha1) and ACE (I/D) gene polymorphisms with type 2 diabetes mellitus in north west India. Diabetes Res Clin Pract 74:95-102 (Pubitemid 44810196)
33. Powell DS, Maksoud H, Charge SB, Moffitt JH, Desai M, Da Silva Fihlo RL et al (2003) Apolipoprotein E genotype, islet amyloid deposition and severity of Type 2 diabetes. Diab Res Clin Pract 60:105-110
34. Souza DR, Nakachima L, Biagioni RB, Nakazone MA, Pinhel MA, Trindade DM, Mafra VT, Tacito LH, Martin JF, Pinheiro Junior S, Brandao AC (2007) Relevance of apolipoprotein E4 for the lipid profile of Brazilian patients with coronary artery disease. Braz J Med Biol Res 40(2):189-197
35. Altamirano CV, Bartels CF, Lockridge O (2000) The butyrylcholinesterase K-variant shows cellular protein turnover and quaternary interaction to the wild-type enzyme. J Neurochem 74:869-877
36. Thomas T, Thomas G, Mclendon C, Sutton T, Mullan M (1996) b-amyloid mediated vasoactivity, and vascular endothelial damage. Nature 380:168-171
37. Randell EW, Mathews MS, Zhang H, Seraj JS, Sun G (2005) Relationship between serum butyrylcholinesterase and the metabolic syndrome. Clin Biochem 38:799-805
38. Vaisi Raygani A, Tavilani H, Rahimi Z, Zahrai M, Sheikh N, Aminian M, Pourmotabbed T (2009) Serum butyrylcholinesterase activity and phenotype associations with lipid profile in stroke patients. Clin Biochem 42:210-214